Zobrazit v EDS

Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be)

Uloženo v:
Podrobná bibliografie
Název: Factors associated with therapeutic response to adalimumab in hidradenitis suppurativa: evidence from the Belgian patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be)
Autoři: Mathieu Daoud, Farida Benhadou, Mariano Suppa, Anne-Sophie Sarkis, Stéphanie Heudens, Lila Desmarest, Hassane Njimi, Mathilde Daxhelet, Laura Nobile, Jalila Karama, Jonathan M. White, Gregor B. E. Jemec, Véronique del Marmol
Zdroj: Archives of Dermatological Research. 317
Informace o vydavateli: Springer Science and Business Media LLC, 2025.
Rok vydání: 2025
Témata: Male, Adult, Anti-Inflammatory Agents, Adalimumab -- therapeutic use, Severity of Illness Index, Young Adult, Belgium, Belgium -- epidemiology, Humans, Registries, Outcome, Retrospective Studies, Dermatologie, Hidradenitis Suppurativa -- drug therapy, Adalimumab, Registries -- statistics & numerical data, Middle Aged, Hidradenitis Suppurativa, Hidradenitis suppurativa, Treatment Outcome, Phenotype, Personalised medicine, Female, Scoring, Anti-Inflammatory Agents -- therapeutic use, Predictor
Popis: Hidradenitis suppurativa is an inflammatory skin disease for which adalimumab is an effective treatment in just over half of cases. Few factors associated with therapeutic response, and therefore potentially predictive of response, are known to date. This real-life study retrospectively explores the existence of such factors in a Belgian cohort of 82 patients, using several response scores: the Hidradenitis Suppurativa Clinical Response (HiSCR), the International Hidradenitis Suppurativa Severity Scoring System-55 (iHS4-55), and the dynamic metascore (a combination of the Hurley score, the 2007 version of the Sartorius score, the iHS4 and the HiSCR). Among the factors associated with a good therapeutic response, we find, for example, the "Frictional furunculoid" and "Conglobata" phenotypes, in contrast to the "Scarring folliculitis" phenotype, which is associated with a poorer response to treatment. Other factors associated with a good response to treatment were observed, such as the patient's description of longer flares, or, among others, the presence of inflammatory bowel disease. Subject to our sample size, the window of opportunity for adalimumab, whereby the treatment would be more effective if administered earlier, was not found in this study.
Druh dokumentu: Article
Popis souboru: 2 full-text file(s): application/pdf; application/pdf
Jazyk: English
ISSN: 1432-069X
DOI: 10.1007/s00403-024-03675-w
Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/39775946
Rights: Springer Nature TDM
Přístupové číslo: edsair.doi.dedup.....e682f837f929fb7da6f63a938c878bb0
Databáze: OpenAIRE
Popis
Abstrakt:Hidradenitis suppurativa is an inflammatory skin disease for which adalimumab is an effective treatment in just over half of cases. Few factors associated with therapeutic response, and therefore potentially predictive of response, are known to date. This real-life study retrospectively explores the existence of such factors in a Belgian cohort of 82 patients, using several response scores: the Hidradenitis Suppurativa Clinical Response (HiSCR), the International Hidradenitis Suppurativa Severity Scoring System-55 (iHS4-55), and the dynamic metascore (a combination of the Hurley score, the 2007 version of the Sartorius score, the iHS4 and the HiSCR). Among the factors associated with a good therapeutic response, we find, for example, the "Frictional furunculoid" and "Conglobata" phenotypes, in contrast to the "Scarring folliculitis" phenotype, which is associated with a poorer response to treatment. Other factors associated with a good response to treatment were observed, such as the patient's description of longer flares, or, among others, the presence of inflammatory bowel disease. Subject to our sample size, the window of opportunity for adalimumab, whereby the treatment would be more effective if administered earlier, was not found in this study.
ISSN:1432069X
DOI:10.1007/s00403-024-03675-w